{"id":85467,"date":"2018-12-04T08:42:36","date_gmt":"2018-12-04T16:42:36","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2018\/12\/is-curing-patients-a-sustainable-business-model-goldman-sachs-analysts-ask"},"modified":"2018-12-04T08:42:36","modified_gmt":"2018-12-04T16:42:36","slug":"is-curing-patients-a-sustainable-business-model-goldman-sachs-analysts-ask","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2018\/12\/is-curing-patients-a-sustainable-business-model-goldman-sachs-analysts-ask","title":{"rendered":"\u201cIs curing patients a sustainable business model?\u201d Goldman Sachs analysts ask"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/is-curing-patients-a-sustainable-business-model-goldman-sachs-analysts-ask.jpg\"><\/a><\/p>\n<p>Analyst Salveen Richter and colleagues laid it out:<\/p>\n<blockquote><p>The potential to deliver \u201cone shot cures\u201d is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies\u2026 While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.<\/p><\/blockquote>\n<p>For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company\u2019s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year.<\/p>\n<p><!-- Link: <a href=\"https:\/\/arstechnica.com\/tech-policy\/2018\/04\/curing-disease-not-a-sustainable-business-model-goldman-sachs-analysts-say\/\">https:\/\/arstechnica.com\/tech-policy\/2018\/04\/curing-disease-n...lysts-say\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Analyst Salveen Richter and colleagues laid it out: The potential to deliver \u201cone shot cures\u201d is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies\u2026 While this proposition carries tremendous value for [\u2026]<\/p>\n","protected":false},"author":499,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,43,412,17],"tags":[],"class_list":["post-85467","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-business","category-genetics","category-sustainability"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/85467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/499"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=85467"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/85467\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=85467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=85467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=85467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}